Y291C

Category 3/4 — Most DruggableUncertain significanceCytoplasmic · predictedSource card

Tyrosine → Cysteine at position 291 · N-terminal cytoplasmic (intrinsically disordered) · WFS1 (Wolframin)

Interactive 3D Structure

Wild-type reference

Wild-type Y291 — hydrogen bond to H294

Fullscreen ↗

DynaMut2 mutant · Y291C

Mutant C291 — hydrogen bond contact to H294 lost

Fullscreen ↗

Bond changes · DynaMut2 interaction analysis

1 lost2 gained8 preserved

Interaction type	Wild-type partner	Mutant partner	Status
Hydrogen bond	K287	K287	Preserved
Hydrogen bond	H294	H294	Preserved
Hydrogen bond	A295	A295	Preserved
Polar contact	K287	K287	Preserved
Polar contact	L293	L293	Preserved
Polar contact	H294	H294	Preserved
Polar contact	A295	—	Lost
Carbonyl	K287	K287	Preserved
Van der Waals	—	K287	Gained
Van der Waals	L293	L293	Preserved
Hydrophobic	—	H294	Gained

Lost / gained / preserved interatomic contacts at the variant residue, from the DynaMut2 (Arpeggio) interaction analysis of the wild-type and energy-minimized mutant structures.

Computational Predictions

DynaMut2 ΔΔG

0.55kcal/mol

Stabilising — mild

AlphaMissense

0.865

likely pathogenic

AlphaFold pLDDT

model confidence

Schema

Cat 3/4

Category 3/4 — Most Druggable

Clinical Evidence

ClinVar classificationUncertain significance

Review statuscriteria provided, multiple submitters, no conflicts

Associated conditionsAutosomal dominant nonsyndromic hearing loss 6; WFS1-Related Spectrum Disorders; Wolfram syndrome 1

Population frequency (gnomAD v4)Absent from gnomAD v4

cDNA changec.872A>G

ClinVar accessionVCV000904804

Last evaluated2018/01/13 00:00

Not observed in ~730k individuals — consistent with a rare allele (ACMG PM2_supporting).

Full Variant Card

WFS1 Wolframin — Y291C Variant Card

Molecular Atlas Pilot · RareResearch.AI · Generated by wolfram-variant-card skill

Tyrosine → Cysteine at position 291. N-terminal cytoplasmic (intrinsically disordered). ClinVar Uncertain significance, AlphaMissense 0.865, DynaMut2 ΔΔG +0.55 kcal/mol (stabilising).

Identity

Field	Value
Variant	Y291C (p.Tyrosine291Cysteine)
DNA change	c.872A>G
Gene · Protein	WFS1 · Wolframin (890 aa)
UniProt	O76024 · WFS1_HUMAN
ClinVar accession	VCV000904804
Amino acid change	Tyrosine (Y) → Cysteine (C)

Structural Context

Field	Value
AlphaFold model	AF-O76024-F1, v6
pLDDT at residue 291	65.31 — confident
Domain	N-terminal cytoplasmic (intrinsically disordered)
Position context	N-terminal cytoplasmic (intrinsically disordered)
IDR flag	No — pLDDT above 50 threshold

UniProt features at this position:

(none catalogued)

Position 291 sits in N-terminal cytoplasmic (intrinsically disordered). The wild-type residue is aromatic with hydroxyl (tyrosine — H-bond donor/acceptor); the mutant is thiol (cysteine — disulfide-capable, free -SH). The chemistry shift implies altered local packing, hydrogen-bonding, and/or electrostatics at this site.

Computational Predictions

AlphaMissense

Field	Value
am_pathogenicity	0.8647
am_class	likely pathogenic
Interpretation	Likely pathogenic (threshold 0.564)

DynaMut2

Field	Value
ΔΔG (kcal/mol)	0.55 (Stabilising)
Job ID	178092110512
Result URL	https://biosig.lab.uq.edu.au/dynamut2/results_prediction/178092110512

Clinical Evidence

Field	Value
Classification	Uncertain significance
Review status	criteria provided, multiple submitters, no conflicts
Last evaluated	2018/01/13 00:00
Inheritance	Autosomal dominant pattern indicated by associated DFNA6/14/38 (WFS1 hearing loss 6).
WFS1 variant landscape	Y291C is 1 of ~326 pathogenic-spectrum variants in WFS1 (out of 2,243 catalogued in ClinVar)

Autosomal dominant nonsyndromic hearing loss 6
WFS1-Related Spectrum Disorders
Wolfram syndrome 1

Research Path Decision Tree

ΔΔG < 2  + binding site affected   →  CATEGORY 3 — docking experiments
ΔΔG 2–4                            →  CATEGORY 2 — pharmacological chaperones
ΔΔG > 4                            →  CATEGORY 1 — gene therapy
pLDDT < 50                         →  CATEGORY 5 — IDR, experimental only
Stable fold + functional site hit  →  CATEGORY 4 — site-specific docking

Final Schema Categorization

Category 3/4 — Most Druggable

<strong>Category 3/4 — Most Druggable</strong><br/><br/>|ΔΔG|=0.55 < 2 kcal/mol (fold intact) + AlphaMissense 0.865 confirms functional impact. Specific local contacts disrupted — priority for docking and pharmacological chaperone screening.

Why this card matters. Wolframin's fold survives this substitution (|ΔΔG|=0.55 kcal/mol). The pathogenic signal is real — AlphaMissense places it at 0.865. Protein still folds, but a specific local site is broken. Pharmacological chaperones and small-molecule binders are the rational therapeutic vector.

Files in this folder

AF-O76024-F1-model_v6.pdb — AlphaFold structure
Y291C_molstar_viewer.html — interactive 3D viewer (auto-highlights position 291 with ball-and-stick + neighbors within 5Å)
Y291C_variant_card.md — this card (source of truth)
Y291C_variant_card.html — styled printable card
Y291C_dynamut2_summary.html — clean offline DynaMut2 result card
dynamut2_result.json — structured result data
dynamut2_result_page.html — local snapshot of the Biosig result page (asset URLs absolutized)
Y291C_wildtype_interactions.pse / Y291C_mutant_interactions.pse — PyMOL sessions

Generated by wolfram-variant-card skill · RareResearch.AI Molecular Atlas Every assumption documented. Every score sourced.

Therapeutic Strategy Handoff · prediction

Feed this card to Wolfram Intelligence

Download the Y291C PDF below and upload it to Wolfram Intelligence to generate therapeutic-strategy proposals — guanidinium mimetics, sigma-1 agonist docking, NAC thiol-capping. NAC is already on the bench-testing list.

Download Y291C PDF card ↓Strategies are AI-generated predictions, not validated therapeutics.